GEROTHERAPEUTIX
LIVE

Serial Number

99059580

Owner

SENOTHERAPEUTIX, Inc.

Attorney

Jared L. DuJack

Filing Date

Feb 27, 2025

Add to watchlist:

No watchlists yet
View on USPTO

GEROTHERAPEUTIX Trademark

Serial Number: 99059580

GEROTHERAPEUTIX is a trademark filed by SENOTHERAPEUTIX, Inc. on February 27, 2025. The trademark is classified under Class 3 (Cosmetics & Cleaning), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

SENOTHERAPEUTIX, Inc. (2 trademarks)

9511 Collins Avenue #1403
Surfside, FL 33154

Entity Type: 03

Trademark Details

Filing Date

February 27, 2025

Registration Date

Not Registered

Goods & Services

Anti-aging cream; Non-medicated anti-aging serum; Cosmetic anti-aging products, namely, anti-aging creams, serums, moisturizers, tonics, and cleansers; Cosmetic preparations; Cosmetic creams for skin care; Cosmetic preparations for skin care

Anti-aging therapy; Medical services, namely, anti-aging services; Medical testing services, namely, biologic age scoring; Medical testing services in the nature of statistical scoring to determine a biologic age score of a patient; Medical services; Medical services, namely, anti-aging services; Medical services, namely, prevention and treatment of age-related disorders; Medical advisory services; Medical advisory services, namely, anti-aging services; Medical advisory services, namely, prevention and treatment of age-related disorders; Medical testing services; Medical testing services, namely, anti-aging services; Medical testing services, namely, prevention and treatment of age-related disorders; Medical services in the field of anti-aging; Medical services in the field of senescent cells; Medical services in the field of age-related disorders; Medical testing services, namely, biopsy services; Medical testing services, namely, biopsy services related to biologic age; Medical testing services, namely, biopsy services related to biological age scoring; Medical testing services, namely, biopsy services related to determining a number or percentage of senescent cells; Laboratory services being medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Laboratory services related to biologic age, namely medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Laboratory services related to biological age scoring, namely medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories, namely, laboratory services related to determining a number or percentage of senescent cells; Non-invasive medical testing; Non-invasive medical testing related to biologic age; Non-invasive medical testing related to biological age scoring; Non-invasive medical testing related to determining a number or percentage of senescent cells; Medical care, namely, prevention of radiation damage; Medical care, namely, treatment of radiation damage; Medical care, namely, prevention of radiation related diseases; Medical care, namely treatment of radiation related diseases; Medical care, namely, treatment of obesity; Providing weight loss program services in the nature of weight loss regimens; Medical care, namely, treatment of obesity in combination with other drugs; Consulting services in the fields of medical care pertaining to anti-aging and cosmetics; Medical skin care services, namely, biologic age scoring for use in cosmetics; Medical care, namely, statistical scoring to determine a biologic age score of an individual

Pharmaceutical products for the prevention and treatment of cancer and other age-related skin disorders; Gene therapy-based pharmaceutical products for the prevention and treatment of cancer and other age-related skin disorders; Synthesized peptides for use in treating age-related diseases and cancer; Synthesized peptides for use in skin conditions; Synthesized peptides, namely anti-aging peptides; Synthesized peptides for use in prevention of radiation damage; Synthesized peptides for use in treatment of radiation damage; Synthesized peptides for use in prevention of radiation related diseases; Synthesized peptides for use in treatment of radiation related diseases; Synthesized peptides for use in treatment of obesity; Synthesized peptides for use in weight loss regimens, Synthesized peptides for use in treatment of obesity in combination with other drugs; Synthesized peptides, namely, peptides for use in cosmetics; Synthesized peptides, namely, anti-aging peptides for use in cosmetics

Development of pharmaceutical preparations and medicines; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Testing, inspection, research, and development of pharmaceutical preparations for age therapy and gene therapy; Consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; Cosmetic research; Development of cosmetic preparations; Research and development of cosmetic preparations; Gene therapy research; Gene therapy research related to anti-aging; Gene therapy research related to cancer; Gene therapy related to prevention and treatment of radiation damage and radiation related diseases; Gene therapy related to treatment of obesity; Gene therapy related to weight loss regimens; Gene therapy related to treatment of obesity in combination with other drugs; Anti-aging research; Medical research services; Medical research services, namely, anti-aging services; Medical research services, namely, prevention and treatment of age-related disorders

Filing History

NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 11, 2026 GNRN
NON-FINAL ACTION E-MAILED
May 11, 2026 GNRT
NON-FINAL ACTION WRITTEN
May 11, 2026 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 25, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 25, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 25, 2026 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Dec 15, 2025 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Dec 15, 2025 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 25, 2025 GNRN
NON-FINAL ACTION E-MAILED
Sep 25, 2025 GNRT
NON-FINAL ACTION WRITTEN
Sep 25, 2025 CNRT
ASSIGNED TO EXAMINER
Sep 10, 2025 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Sep 9, 2025 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 9, 2025 NWOS
APPLICATION FILING RECEIPT MAILED
Feb 27, 2025 MAFR
NEW APPLICATION ENTERED
Feb 27, 2025 NWAP